Skip to main
PTHS
PTHS logo

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics has demonstrated significant growth potential, with a dramatic increase in the projected 4Q revenue to $16.2 million, boosted by a greater than 40% increase in prescription volumes in October. This growth is linked to an increase in the number of prescriptions written, with the company reporting a 41% sequential rise in October, exceeding the total volume from the previous quarter in just the first seven weeks of 4Q. Additionally, the expansion of the sales force from 50 to 64 territory managers aims to enhance clinician coverage from approximately 8,000 to 10,000, positioning Pelthos for greater market penetration and revenue growth in the coming year.

Bears say

Pelthos Therapeutics faces significant challenges that contribute to a negative outlook for its stock. Specifically, the company may struggle with market penetration and revenue growth due to potential issues with reimbursement, formulary placement, and adoption by key healthcare providers. Additionally, competitive pressures from alternative therapies and risks associated with clinical trials, funding, and operational execution could further hinder the company’s ability to achieve its projected financial performance.

PTHS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Strong Buy based on their latest research and market trends.

According to 4 analysts, PTHS has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.